Deal Snapshot
Histogen Closes Merger with Conatus Pharmaceuticals
Thursday 28 May 2020

US-based regenerative medicine company Histogen Inc. (NASDAQ: HSTO) has closed a merger with Conatus Pharmaceuticals Inc, the company said.

The combined company changed its name to Histogen Inc. and will focus on developing patented technologies that replace and regenerate tissues in the body. Histogen began on May 27, 2020, on The NASDAQ Capital Market under the ticker symbol "HSTO." Histogen will maintain its headquarters in San Diego, California and will be led by president and chief executive officer, Richard W. Pascoe.

Date Published: 28/05/2020